Payment overview · 2025
General Payments
$2,542.84
47 reported records · 15 companies
Healthcare provider profile · identity verified
Cesar Figueroa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DELRAY BEACH, FL · NPI 1063575231
Verified facts
What the public records show
CMS Open Payments records show Cesar Figueroa, MD received $2,542.84 in general payments during 2025 across 47 reported records.
Abbott Laboratories accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Prolia, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $527.69 | 20.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $503.05 | 19.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $310.78 | 12.2% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $228.84 | 9.0% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $192.39 | 7.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.25 | 7.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $140.31 | 5.5% | 2 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $124.99 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.53 | 3.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $81.08 | 3.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $41.38 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $39.02 | 1.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.33 | 1.1% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $25.28 | 1.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.92 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,542.84 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $489.71 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $310.78 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $258.20 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $228.84 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $192.39 | 5 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $187.63 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $180.19 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $142.75 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $140.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.42 | 2 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.03 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.44 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $41.38 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| OXLUMO Normalized: oxlumo |
Drug | Alnylam Pharmaceuticals Inc. | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 35 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 84 |
| Ezetimibe | Ezetimibe | 299 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 98 |
| Losartan Potassium | Losartan Potassium | 269 | 84 |
| Metformin Hcl Er | Metformin Hcl | 211 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 69 |
| Nifedipine Er | Nifedipine | 203 | 62 |
| Carvedilol | Carvedilol | 192 | 53 |
| Gabapentin | Gabapentin | 182 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 164 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 49 |
| Lisinopril | Lisinopril | 153 | 39 |
| Famotidine | Famotidine | 145 | 34 |
| Eliquis | Apixaban | 141 | 22 |
| Xarelto | Rivaroxaban | 141 | 17 |
| Omeprazole | Omeprazole | 133 | 52 |
| Alendronate Sodium | Alendronate Sodium | 126 | 39 |
| Metformin Hcl | Metformin Hcl | 113 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 32 |
| Farxiga | Dapagliflozin Propanediol | 102 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 29 |
| Ozempic | Semaglutide | 85 | 20 |
| Sertraline Hcl | Sertraline Hcl | 82 | 27 |
| Finasteride | Finasteride | 74 | 25 |
| Jardiance | Empagliflozin | 74 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 18 |
| Glipizide Er | Glipizide | 66 | 21 |
| Trazodone Hcl | Trazodone Hcl | 64 | 24 |
| Vascepa | Icosapent Ethyl | 59 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 17 |
| Clonazepam | Clonazepam | 53 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 14 |
| Baclofen | Baclofen | 51 | suppressed |
| Allopurinol | Allopurinol | 50 | 15 |
| Donepezil Hcl | Donepezil Hcl | 50 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 16 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 16 |
| Labetalol Hcl | Labetalol Hcl | 41 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | suppressed |
| Prednisone | Prednisone | 39 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 27 |
| Ciclopirox | Ciclopirox | 37 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Prolia | Denosumab | 35 | 20 |
| Temazepam | Temazepam | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 23 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Montelukast Sodium | Montelukast Sodium | 31 | 13 |
| Furosemide | Furosemide | 30 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | 11 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Celecoxib | Celecoxib | 16 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Meloxicam | Meloxicam | 14 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Blisovi Fe | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,542.84 · 47 records | Abbott Laboratories | ADBRY, AIRSUPRA, AMPLATZER AMULET, Cologuard Collection Kit, ENSITE, EVENITY, FARXIGA, KISUNLA, Kerendia, Korlym, MITRACLIP, MOUNJARO, OXLUMO, Ozempic, PERCLOSE PROSTYLE, PROLIA, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, WATCHMAN FLX, XIFAXAN, ZEPBOUND, ZORYVE, Zypitamag | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error